|
KMID : 1141920210370000039
|
|
Annals of Coloproctology
2021 Volume.37 No. 0 p.39 ~ p.43
|
|
|
Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
|
|
Cho Hye-Jung
Kim Woo-Ram
Kim Joo-Hang
Kim Duk-Hwan
Kim Dae-Jung
Kang Hae-Youn
|
|
|
Abstract
|
|
|
|
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
|
|
|
KEYWORD
|
|
|
Nivolumab, Intestinal perforation, Drug-related side effects and adverse reactions, Immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|